COVID-19 Press Releases

  • USask’s VIDO announces positive Phase 1 results for COVAC-2

    The Vaccine and Infectious Disease Organization at the University of Saskatchewan announced positive interim results from their Phase 1 clinical trial for COVAC-2, VIDO’s COVID-19 subunit vaccine candidate.

  • USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

    The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization at the University of Saskatchewan.

  • VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval

    The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan has received a notice of authorization from Health Canada to initiate a Phase 1 clinical vaccine trial.

  • New CT scanner gives USask’s VIDO-InterVac scientists a window on COVID-19 disease

    New imaging equipment to help understand COVID-19 infection will soon be coming to the VIDO-InterVac at the USask, thanks to a Canada Foundation for Innovation grant announced today by Prime Minister Justin Trudeau.

  • Extending the lifespan of N95 masks

    Researchers at the CLS and VIDO-InterVac are working together to better understand how decontamination procedures might affect the structure and potential reuse of N95 masks.

  • USask VIDO-InterVac expands international role to test antiviral compounds against COVID-19

    VIDO-InterVac at the University of Saskatchewan has been awarded a grant of almost $830,000 from the COVID-19 Therapeutics Accelerator to determine the effectiveness of several antiviral compounds against COVID-19.

  • Dalton Partners with VIDO-InterVac to Combat COVID-19

    Dalton Pharma Services will be responsible for the formulation and fill/finish of VIDO-InterVac’s innovative COVID-19 vaccine, to be used in early Phase clinical trials.

  • Canadian universities partner to fight COVID-19 at USask’s VIDO-InterVac

    Infectious disease experts from Dalhousie University and University of Manitoba are joining the leading-edge research team at VIDO-InterVac on one-year secondments to collaboratively advance research and development against COVID-19.

  • Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine

    A COVID-19 vaccine candidate developed by VIDO-InterVac has cleared another major milestone in moving towards human clinical trials: the novel vaccine has proven highly effective in ferrets, one of the commonly used animal models for COVID-19.

  • USask’s VIDO-InterVac and the National Research Council of Canada collaborate to advance development of vaccine against COVID-19

    VIDO-InterVac and NRC announced a collaboration to accelerate the development and production of a candidate COVID-19 antigen in mammalian cells.

  • ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19

    ZYUS Life Sciences Inc. and VIDO-InterVac will collaborate to test plant produced antigens in a vaccine for COVID-19.

  • USask VIDO-InterVac awarded $23M for COVID-19 vaccine research

    VIDO-InterVac has been awarded $23 million to fast-track efforts to develop a COVID-19 vaccine, Prime Minister Justin Trudeau announced today.

  • Prime Minister announces new support for COVID-19 medical research and vaccine development

    $23 million announced to accelerate development of a vaccine against COVID-19. Funding will support pre-clinical testing and clinical trials of a potential COVID-19 vaccine, essential steps to ensuring that vaccines are effective and safe for human use.

  • SHA and VIDO-InterVac partner to help ensure supply of N95 respiratory masks

    The Saskatchewan Health Authority and VIDO-InterVac at the University of Saskatchewan are partnering on a way to safely decontaminate and reuse N95 respiratory masks that are normally thrown away after each use.

  • USask VIDO-InterVac and International Vaccine Institute collaborate on COVID-19 work

    IVI of South Korea, a world-renowned international organization founded by the United Nations Development Programme, is collaborating with VIDO-InterVac to better understand the virus causing COVID-19 and to develop vaccines and potential treatments.

  • Saskatchewan government invests $3.6M in USask COVID-19 vaccine research

    The Government of Saskatchewan has announced $3.6 million in new funding for VIDO-InterVac one of the world’s most advanced infectious disease labs and a leader in global efforts to find a COVID-19 vaccine.

  • New Money Aids Saskatchewan’s Search For Covid-19 Vaccine

    The Government of Saskatchewan and the Federal Government are committing $28 million to VIDO-InterVac to develop a vaccine for COVID-19.

  • PM announces $12M for new vaccine manufacturing at USask’s VIDO-InterVac, part of $23.3M for the lab to fight COVID-19 and other infectious disease threats

    As the COVID-19 outbreak continues to rapidly evolve, the federal government announced $23.3 million to support VIDO-InterVac, one of the largest and most advanced infectious disease research facilities in the world.

  • Canada’s plan to mobilize science to fight COVID-19

    Funding to strengthen COVID-19 vaccine development and expand bio-manufacturing capacity to support clinical trials

  • Saskatchewan Funds Coronavirus Vaccine Research

    Innovation Saskatchewan is providing researchers at the VIDO-InterVac with $200,000 to help find a vaccine for COVID-19.

  • VIDO-InterVac-led research team at USask awarded almost $1M to fight new coronavirus

    Researchers and collaborating scientists from across the country have been awarded almost $1 million over two years to develop animal models and test vaccine candidates for effectiveness and safety against the new coronavirus.

  • VIDO-InterVac approved to work on SARS-CoV-2

    Researchers have received permission from the Public Health Agency of Canada to start working on a vaccine for the coronavirus recently discovered in China, and they hope to have first candidates for testing in an animal model in six to eight weeks.